Welcome to our dedicated page for Alvotech news (Ticker: ALVO), a resource for investors and traders seeking the latest updates and insights on Alvotech stock.
Alvotech (NASDAQ: ALVO) is a biotechnology company dedicated exclusively to biosimilars, and its news flow reflects the progress of a global biosimilar platform. Company updates frequently cover regulatory milestones, such as marketing authorizations in the European Economic Area, the United Kingdom and Japan for products referencing Prolia and Xgeva (denosumab), Simponi (golimumab) and Eylea (aflibercept). Press releases also highlight clinical and regulatory developments for new candidates, including submissions to agencies like the European Medicines Agency and the U.S. Food and Drug Administration.
Investors following ALVO news can expect regular announcements on product approvals, pipeline progress and legal or regulatory outcomes. Recent communications have described European Commission approval of AVT03, a biosimilar to Prolia and Xgeva, positive opinions from EMA committees for AVT03 and AVT05, and a settlement and license agreement enabling a future U.S. launch of AVT06, a proposed biosimilar to Eylea, subject to FDA approval. Other items include court decisions related to manufacturing activities for AVT06 and updates on applications for additional candidates such as AVT23.
Alvotech’s news flow also includes capital markets and financing transactions, such as senior unsecured convertible bond offerings and a senior term loan facility, which the company states are intended to support its research and development pipeline, manufacturing capacity and global product launches. Earnings-related press releases and business updates provide guidance ranges for revenues and adjusted EBITDA, along with commentary on order books, launch timing and investment programs.
Corporate governance and leadership changes are another recurring theme. For example, Alvotech has announced a planned CEO succession in which the founder will remain as Executive Chairman while a new Chief Executive Officer takes over day-to-day leadership. For users tracking ALVO, this news page offers a centralized view of regulatory, financial and strategic developments affecting the company’s biosimilar portfolio and global partnerships.
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines, has appointed Dr. Balaji V. Prasad as Chief Strategy Officer. Dr. Prasad brings 25 years of pharmaceutical industry experience, combining medical expertise with financial analysis background. He previously served as a director and equities analyst at Barclays, covering US specialty pharma. His credentials include an MD from Bangalore Medical College and an MBA from IIM Ahmedabad.
Prior roles include portfolio management at a Swiss asset management firm and leadership positions at Barclays and Goldman Sachs' India healthcare coverage. Chairman and CEO Róbert Wessman highlighted Dr. Prasad's deep understanding of Alvotech's business and product pipeline as key assets for the company's growth.
Alvotech (NASDAQ: ALVO), Kashiv Biosciences, and Advanz Pharma announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted a marketing application for AVT23, a proposed biosimilar to Xolair® (omalizumab). The biosimilar targets treatments for severe persistent allergic asthma and chronic rhinosinusitis with nasal polyps.
Xolair recorded global sales of $4.4 billion in 2024. The development builds on previous partnerships, including a February 2023 commercialization agreement between Alvotech and Advanz Pharma for AVT23, which was expanded in May 2023 to include five additional biosimilar candidates. Additionally, Alvotech and Kashiv established a licensing agreement for AVT23 in October 2023.
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines, has announced plans to list Swedish Depository Receipts (SDRs) on Nasdaq Stockholm. The listing follows Alvotech's acquisition of Xbrane Biopharma's R&D operations and aims to expand its investor base in Nordic and European markets. The offering includes 441,600 SDRs with an estimated gross proceeds of SEK 30 million, with each SDR representing one share.
The offering price will be set at the lower of the volume-weighted average price or closing price of Alvotech shares on Nasdaq Iceland during the application period (May 9-16, 2025), with a 10% discount and capped at SEK 90 per SDR. Trading is expected to commence on May 19, 2025, under the ticker "ALVO SDB". Existing shareholders will have a one-year free conversion period to convert their shares into SDRs.
Alvotech (NASDAQ: ALVO), a global biotech company specializing in biosimilar medicines, has announced that potential U.S. tariffs on imported pharmaceuticals should have minimal impact on its 2025 product revenues. The company, which manufactures its biosimilars in Iceland, faces a minimum 10% tariff on U.S. imports. This tariff would increase costs for U.S. customers by less than 1% of Alvotech's expected 2025 product revenues.
According to contracted terms, customers are responsible for transport costs and import duties, not Alvotech. CEO Robert Wessman noted that Iceland's favorable trade balance with the U.S. makes higher tariffs unlikely, and emphasized that biosimilars remain the most cost-effective way to increase patient access to vital biologics. Beyond 2025, even with anticipated product launches and increased sales, the tariff impact would still represent a low single-digit percentage of total product revenues.
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, has scheduled its first quarter 2025 financial results announcement. The company will release its Q1 2025 results after U.S. markets close on May 7, 2025, followed by an analyst conference call on May 8, 2025, at 8:00 am EDT (14:00 CET).
The conference call will be accessible via webcast to media, investors, and the public through Alvotech's investor website. The webcast recording will remain available for replay for 90 days after the event.
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, has scheduled its first quarter 2025 financial results announcement. The company will release its Q1 2025 results after U.S. markets close on Wednesday, May 7, 2025.
A conference call with analysts to discuss financial results and recent business highlights will be held on Thursday, May 8, 2025, at 8:00 am EDT (12:00 noon GMT, 14:00 CET). The event will be accessible via webcast through Alvotech's investor website, with a 90-day replay period available after the presentation.
Teva Pharmaceuticals and Alvotech have announced the U.S. launch of SELARSDI™, their second biosimilar under their strategic partnership. SELARSDI, a biosimilar to Stelara® (ustekinumab), received FDA approval in October 2024 for treating multiple conditions including psoriatic arthritis, plaque psoriasis, Crohn's disease, and ulcerative colitis in both adults and children.
The FDA has provisionally determined SELARSDI's interchangeability with Stelara® following April 30, 2025. The drug is available in four presentations matching Stelara's approved formats. This launch follows their first biosimilar SIMLANDI®, approved in February 2024 and launched in May 2024.
Under the partnership, Alvotech handles development and manufacturing, while Teva manages U.S. commercialization. Their collaboration, initiated in August 2020, now covers seven biosimilar products.